A variation to the clinical staging of AD was proposed by the National Institute on Aging – Alzheimer’s Association (NIA-AA) working group (2018) using six clinical stages for persons who are amyloid positive.
The NIA-AA Research Framework describes AD as a biological construct that can be identified in living persons via Aβ and tau biomarkers.
In the NIA-AA framework, biomarkers are used to identify the presence of AD, with clinical stages used to indicate disease severity.
Read more about New clinical staging of Alzheimer’s disease
